Progress in resistance mechanisms and diagnosis of non-first line anti-TB drugs.
Tuberculosis (TB) is one of the three major infectious diseases in China and all over the world. In 2014, for the first time, TB killed more people than HIV did. Non-first line anti-TB drugs are used as main drugs in the treatment of MDR-TB. However, MDR-TB can gradually develop as extensively drug-resistant TB (XDR-TB) because of poor diagnosis, the unreasonable treatment, poor medical conditions and so on. The death rate of XDR-TB is close to lung cancer. Research on the mechanism of drug resistance of Mycobacterium tuberculosis has turned to non first-line anti-TB drugs: second and third line drugs and some new anti-TB drugs in development. In this review, we summarized the drug resistance mechanisms of the common non-first line anti-TB drugs. Most of drug resistant TB patients can't get timely diagnosis and correct treatment. So at the end of this article, we also summarized the common methods to diagnose drug-resistant TB.
1. State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), Guangzhou 510530, China; 2. Institute of Health Sciences, Anhui University, Hefei 230601, China.
Yang
Y
Liu
State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), Guangzhou 510530, China.
Bang-xing
BX
Wang
State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), Guangzhou 510530, China.
Zhi-yong
ZY
Liu
State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), Guangzhou 510530, China.
Yi
Y
Han
Research Division on Tuberculosis, National Key Laboratory on Respiratory Diseases, Guangzhou Chest Hospital, Guangzhou 510095, China.
Yao-ju
YJ
Tan
Research Division on Tuberculosis, National Key Laboratory on Respiratory Diseases, Guangzhou Chest Hospital, Guangzhou 510095, China.
Xin-jie
XJ
Li
Research Division on Tuberculosis, National Key Laboratory on Respiratory Diseases, Guangzhou Chest Hospital, Guangzhou 510095, China.
Jian-xiong
JX
Liu
Research Division on Tuberculosis, National Key Laboratory on Respiratory Diseases, Guangzhou Chest Hospital, Guangzhou 510095, China.
Shou-yong
S
Tan
State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), Guangzhou 510530, China.
Tian-yu
TY
Zhang
D000995:Antitubercular Agents / Q000494:pharmacology*; D001426:Bacterial Proteins / Q000235:genetics / Q000378:metabolism; D024881:Drug Resistance, Bacterial; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000235:genetics / Q000302:isolation & purification / Q000378:metabolism; D018088:Tuberculosis, Multidrug-Resistant / Q000175:diagnosis* / Q000188:drug therapy / Q000382:microbiology*
D000995:Antitubercular Agents; D001426:Bacterial Proteins